XML 32 R15.htm IDEA: XBRL DOCUMENT
v3.19.1

Common Stock | 12 Months Ended
--- | ---
Jan. 31, 2019
Equity [Abstract] |
COMMON STOCK |
9. | COMMON STOCK
The Company issued 322,000 shares of common stock valued at $1,763,950, based on the market price on the date of issuance, during the year ended January 31, 2019 for services provided to the Company. Of these shares, 272,000 shares valued at $1,419,300 were issued to executives of the Company and 30,000 shares valued at $222,000 were issued to directors of the Company. On May 2, 2018, the Company sold to an unrelated party for $1.0 million, 250,000 shares of common stock and 30-day warrants to purchase 250,000 shares of common stock at $4.00 per share. On May 27, 2018, the unrelated party exercised warrants to purchase 125,000 shares of common stock for proceeds of $500,000 and on June 2, 2018, warrants to purchase 125,000 shares of common stock expired unexercised. On July 31, 2018, the Company issued 250,000 shares of common stock valued at $1,850,000 representing a portion of the purchase price for the equity of 4P Therapeutics. See Note 5. On November 23, 2018, the Company issued 71,429 shares of its common stock and received proceeds of $500,000 from TII Jet Services LLC. In November 2018, one of the defendants in the legal proceedings with Advanced Health Brands, Inc., returned 200,000 shares of common stock that had been issued to her, and these shares were cancelled as of January 31, 2019.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration